SCHEMBL2805827

SCHEMBL2805827

CC(C)C#Cc1ncc(C(=O)NS(=O)(=O)c2ccccc2S(N)(=O)=O)cc1Cl

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PTGES O14684 2/20 0.48
CA1 P00915 8/20 0.37
CA2 P00918 8/20 0.37
CA9 Q16790 4/20 0.37
CA12 O43570 3/20 0.37
ALKBH2 Q6NS38 1/20 0.36
ALKBH3 Q96Q83 1/20 0.36
P4HTM Q9NXG6 3/20 0.36
CA3 P07451 1/20 0.36
CA4 P22748 1/20 0.36
CA6 P23280 1/20 0.36
CA5A P35218 1/20 0.36
CA7 P43166 1/20 0.36
CA13 Q8N1Q1 1/20 0.36
CA14 Q9ULX7 1/20 0.36
CA5B Q9Y2D0 1/20 0.36
PTGS1 P23219 2/20 0.36
PTGS2 P35354 2/20 0.36
POLB P06746 1/20 0.35
FLT1 P17948 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2807758 0.88 PTGES (0.48) PTGESCA1CA2CA9CA12
SCHEMBL980451 0.87 PTGES (0.49) PTGESCA1CA2CA9CA12
SCHEMBL979757 0.82 PTGES (0.53) PTGESCA1CA2CA9CA12
SCHEMBL976643 0.81 PTGES (0.55) PTGESCA1CA2CA9P4HTM
SCHEMBL977653 0.81 PTGES (0.52) PTGESCA1CA2CA9CA12
SCHEMBL2804226 0.80 PTGES (0.42) PTGESALKBH2ALKBH3
SCHEMBL979484 0.77 PTGES (0.75) PTGESCA1CA2CA9CA12
SCHEMBL979520 0.76 PTGES (0.46) PTGESCA1CA2CA9CA12
SCHEMBL2803069 0.75 PTGES (0.55) PTGESCA1CA2CA9ALKBH2
SCHEMBL2804190 0.74 PTGES (0.50) PTGESCA1CA2CA9CA12

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2010132016-A1 BIS-(SULFONYLAMINO) DERIVATIVES FOR TREATMENT OF PAIN AND INFLAMMATION ASTRAZENECA AB (SE) 2010-11-18 WO claimed
US-20100292279-A1 Bis-(Sulfonylamino) Derivatives in Therapy ASTRAZENECA AB (SE) 2010-11-18 US claimed
WO-2010132016-A1 BIS-(SULFONYLAMINO) DERIVATIVES FOR TREATMENT OF PAIN AND INFLAMMATION ASTRAZENECA AB (SE) 2010-11-18 WO disclosed
US-20100292279-A1 Bis-(Sulfonylamino) Derivatives in Therapy ASTRAZENECA AB (SE) 2010-11-18 US disclosed
US-20100292279-A1 Bis-(Sulfonylamino) Derivatives in Therapy ASTRAZENECA AB (SE) 2010-11-18 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100292279-A1 Bis-(Sulfonylamino) Derivatives in Therapy PTGER1, SULT2A1, SULT1E1 PTGES 9/4885CA1 3748/4885CA2 2726/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.